14 December 2009
Generics Completes Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)
14 December 2009
Generics Completes Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)08 June 2009
Generics Initiates Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)05 February 2009
Ian Kent Appointed as Chairman